Hiding in Plain Sight? Focus on Diagnosing and Addressing the Unmet Needs in Homozygous Familial Hypercholesterolemia
Join PCNA and the American Society for Preventive Cardiology on January 10, 2022 for a complimentary live webcast series. Individuals with HoFH are typically less responsive, or even unresponsive, to standard lipid-lowering therapies such as statins and PCSK9 inhibitors and may benefit from treatment modalities with other mechanisms of action. This curriculum is designed to educate clinicians about the prevalence of heterozygous familial hypercholesterolemia (HeFH) and HOFH, the importance of screening for familial hypercholesterolemia (FH), as well as the benefits and limitations of therapies available for lipid management in patients with HoFH.
Martha Gulati, MD, MS, FACC, FAHA, FASPC, FESC
American Society for Preventive Cardiology
Kathleen Byrne, MSN, CRNP, FPCNA, CLS, FNLA
Cardiovascular Nurse Practitioner
John Hopkins University